Bio-gate AG Total Assets
Bio-gate AG total assets. Based on the latest financial reports, Bio-gate AG (BIG1) holds total assets worth €3.95 Million EUR (≈ $4.61 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Bio-gate AG market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Bio-gate AG (2020–2024)
Total assets of Bio-gate AG from 2020 to 2024. This chart illustrates how Bio-gate AG's total assets have evolved over time, based on quarterly financial data. See BIG1 stock price for real-time trading data and today's change.
Bio-gate AG - Asset Composition Analysis
Bio-gate AG Total Assets Breakdown (December 2024)
Bio-gate AG total assets breakdown as of December 2024. Bio-gate AG's total assets of €3.95 Million consist of 57.0% current assets and 43.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 7.5% |
| Accounts Receivable | €200.46K | 5.1% |
| Inventory | €1.57 Million | 39.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.00 Million | 25.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Bio-gate AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BIG1 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-gate AG's current assets represent 57.0% of total assets in 2024, a decrease from 61.7% in 2020.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, down from 12.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, a decrease from 30.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 39.8% of total assets.
Bio-gate AG Competitors by Total Assets
Key competitors of Bio-gate AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.76 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Caina Technology Co. Ltd.
SHE:301122
|
China | CN¥2.26 Billion |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥1.17 Billion |
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$5.82 Billion |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK
|
Indonesia | Rp980.33 Billion |
|
Medeon Biodesign
TWO:6499
|
Taiwan | NT$1.55 Billion |
|
ZENTEK LTD.
F:ZAY0
|
Germany | €17.38 Million |
Bio-gate AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.13 | 3.48 | 3.48 |
| Quick Ratio | 0.64 | 2.20 | 2.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.20 Million | €2.40 Million | €2.40 Million |
Bio-gate AG - Advanced Valuation Insights
This section examines the relationship between Bio-gate AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.80 |
| Latest Market Cap to Assets Ratio | 1.80 |
| Asset Growth Rate (YoY) | -25.0% |
| Total Assets | €3.95 Million |
| Market Capitalization | $7.12 Million USD |
Valuation Analysis
Above Book Valuation: The market values Bio-gate AG's assets above their book value (1.80x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Bio-gate AG's assets decreased by 25.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bio-gate AG (2020–2024)
The table below shows the annual total assets of Bio-gate AG from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €3.95 Million ≈ $4.61 Million |
-24.96% |
| 2023-12-31 | €5.26 Million ≈ $6.15 Million |
-15.44% |
| 2022-12-31 | €6.22 Million ≈ $7.27 Million |
+19.31% |
| 2021-12-31 | €5.21 Million ≈ $6.09 Million |
+57.46% |
| 2020-12-31 | €3.31 Million ≈ $3.87 Million |
-- |
About Bio-gate AG
Bio-Gate AG provides technologies and customized solutions for health and hygiene in Germany. The company offers HyProtect, a plasma coating which protects the surfaces of medical implants against bacterial colonization; and MicroSilver BG, an elemental microporous silver additive. It distributes its products to veterinarians and veterinary clinics. The company was incorporated in 2005 and is bas… Read more